Go to
JCI Insight
About
Editors
Consulting Editors
For authors
Publication ethics
Alerts
Advertising
Job board
Subscribe
Contact
Current issue
Past issues
By specialty
COVID-19
Cardiology
Gastroenterology
Immunology
Metabolism
Nephrology
Neuroscience
Oncology
Pulmonology
Vascular biology
All ...
Videos
Conversations with Giants in Medicine
Author's Takes
Reviews
Reviews
View all reviews ...
Review Series
Immune Environment in Glioblastoma (Feb 2023)
Korsmeyer Award 25th Anniversary Collection (Jan 2023)
Aging (Jul 2022)
Next-Generation Sequencing in Medicine (Jun 2022)
New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
Immunometabolism (Jan 2022)
Circadian Rhythm (Oct 2021)
View all review series ...
Viewpoint
Collections
In-Press Preview
Commentaries
Research letters
Letters to the editor
Editorials
Viewpoint
Top read articles
Clinical Medicine
JCI This Month
Current issue
Past issues
Do endocannabinoids acting via hepatic CB-1 contribute to NAFLD and hepatic insulin resistance?
George Kunos, … , Tony Jourdan, Joseph Tam
George Kunos, … , Tony Jourdan, Joseph Tam
Published January 4, 2022
Citation Information:
J Clin Invest.
2022;
132(1)
:e155330.
https://doi.org/10.1172/JCI155330
.
View:
Text
|
PDF
Letter to the Editor
Metabolism
Do endocannabinoids acting via hepatic CB-1 contribute to NAFLD and hepatic insulin resistance?
Text
PDF
Abstract
Authors
George Kunos, Tony Jourdan, Joseph Tam
×
Full Text PDF |
Download
(69.70 KB)
